Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy

Kevin G. Shim, Shane Zaidi, Jill Thompson, Tim Kottke, Laura Evgin, Karishma R. Rajani, Matthew Schuelke, Christopher B. Driscoll, Amanda Huff, Jose S Pulido, Richard Geoffrey Vile

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Systemic viroimmunotherapy activates endogenous innate and adaptive immune responses against both viral and tumor antigens. We have shown that therapy with vesicular stomatitis virus (VSV) engineered to express a tumor-associated antigen activates antigen-specific adoptively transferred T cells (adoptive cell therapy, ACT) in vivo to generate effective therapy. The overall goal of this study was to phenotypically characterize the immune response to VSV+ACT therapy and use the information gained to rationally improve combination therapy. We observed rapid expansion of blood CD8+ effector cells acutely following VSV therapy with markedly high expression of the immune checkpoint molecules PD-1 and TIM-3. Using these data, we tested a treatment schedule incorporating mAb immune checkpoint inhibitors with VSV+ACT treatment. Unlike clinical scenarios, we delivered therapy at early time points following tumor establishment and treatment. Our goal was to potentiate the immune response generated by VSV therapy to achieve durable control of metastatic disease. Despite the high frequency of endogenous PD-1+ TIM-3+ CD8+ T cells following virus administration, antibody blockade did not improve survival. These findings provide highly significant information about response kinetics to viroimmunotherapy and juxtapose the clinical use of checkpoint inhibitors against chronically dysfunctional T cells and the acute T cell response to oncolytic viruses.

Original languageEnglish (US)
Pages (from-to)962-975
Number of pages14
JournalMolecular Therapy
Volume25
Issue number4
DOIs
StatePublished - Apr 5 2017

Fingerprint

Vesicular Stomatitis
Viruses
Cell- and Tissue-Based Therapy
Therapeutics
Oncolytic Viruses
Viral Tumor Antigens
Adaptive Immunity
Neoplasm Antigens
Innate Immunity
Appointments and Schedules
Antigens

Keywords

  • checkpoint inhibitors
  • oncolytic virotherapy
  • tumor therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy. / Shim, Kevin G.; Zaidi, Shane; Thompson, Jill; Kottke, Tim; Evgin, Laura; Rajani, Karishma R.; Schuelke, Matthew; Driscoll, Christopher B.; Huff, Amanda; Pulido, Jose S; Vile, Richard Geoffrey.

In: Molecular Therapy, Vol. 25, No. 4, 05.04.2017, p. 962-975.

Research output: Contribution to journalArticle

Shim, KG, Zaidi, S, Thompson, J, Kottke, T, Evgin, L, Rajani, KR, Schuelke, M, Driscoll, CB, Huff, A, Pulido, JS & Vile, RG 2017, 'Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy', Molecular Therapy, vol. 25, no. 4, pp. 962-975. https://doi.org/10.1016/j.ymthe.2017.01.023
Shim, Kevin G. ; Zaidi, Shane ; Thompson, Jill ; Kottke, Tim ; Evgin, Laura ; Rajani, Karishma R. ; Schuelke, Matthew ; Driscoll, Christopher B. ; Huff, Amanda ; Pulido, Jose S ; Vile, Richard Geoffrey. / Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy. In: Molecular Therapy. 2017 ; Vol. 25, No. 4. pp. 962-975.
@article{9435747567b34aaca14ace9879daa62f,
title = "Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy",
abstract = "Systemic viroimmunotherapy activates endogenous innate and adaptive immune responses against both viral and tumor antigens. We have shown that therapy with vesicular stomatitis virus (VSV) engineered to express a tumor-associated antigen activates antigen-specific adoptively transferred T cells (adoptive cell therapy, ACT) in vivo to generate effective therapy. The overall goal of this study was to phenotypically characterize the immune response to VSV+ACT therapy and use the information gained to rationally improve combination therapy. We observed rapid expansion of blood CD8+ effector cells acutely following VSV therapy with markedly high expression of the immune checkpoint molecules PD-1 and TIM-3. Using these data, we tested a treatment schedule incorporating mAb immune checkpoint inhibitors with VSV+ACT treatment. Unlike clinical scenarios, we delivered therapy at early time points following tumor establishment and treatment. Our goal was to potentiate the immune response generated by VSV therapy to achieve durable control of metastatic disease. Despite the high frequency of endogenous PD-1+ TIM-3+ CD8+ T cells following virus administration, antibody blockade did not improve survival. These findings provide highly significant information about response kinetics to viroimmunotherapy and juxtapose the clinical use of checkpoint inhibitors against chronically dysfunctional T cells and the acute T cell response to oncolytic viruses.",
keywords = "checkpoint inhibitors, oncolytic virotherapy, tumor therapy",
author = "Shim, {Kevin G.} and Shane Zaidi and Jill Thompson and Tim Kottke and Laura Evgin and Rajani, {Karishma R.} and Matthew Schuelke and Driscoll, {Christopher B.} and Amanda Huff and Pulido, {Jose S} and Vile, {Richard Geoffrey}",
year = "2017",
month = "4",
day = "5",
doi = "10.1016/j.ymthe.2017.01.023",
language = "English (US)",
volume = "25",
pages = "962--975",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy

AU - Shim, Kevin G.

AU - Zaidi, Shane

AU - Thompson, Jill

AU - Kottke, Tim

AU - Evgin, Laura

AU - Rajani, Karishma R.

AU - Schuelke, Matthew

AU - Driscoll, Christopher B.

AU - Huff, Amanda

AU - Pulido, Jose S

AU - Vile, Richard Geoffrey

PY - 2017/4/5

Y1 - 2017/4/5

N2 - Systemic viroimmunotherapy activates endogenous innate and adaptive immune responses against both viral and tumor antigens. We have shown that therapy with vesicular stomatitis virus (VSV) engineered to express a tumor-associated antigen activates antigen-specific adoptively transferred T cells (adoptive cell therapy, ACT) in vivo to generate effective therapy. The overall goal of this study was to phenotypically characterize the immune response to VSV+ACT therapy and use the information gained to rationally improve combination therapy. We observed rapid expansion of blood CD8+ effector cells acutely following VSV therapy with markedly high expression of the immune checkpoint molecules PD-1 and TIM-3. Using these data, we tested a treatment schedule incorporating mAb immune checkpoint inhibitors with VSV+ACT treatment. Unlike clinical scenarios, we delivered therapy at early time points following tumor establishment and treatment. Our goal was to potentiate the immune response generated by VSV therapy to achieve durable control of metastatic disease. Despite the high frequency of endogenous PD-1+ TIM-3+ CD8+ T cells following virus administration, antibody blockade did not improve survival. These findings provide highly significant information about response kinetics to viroimmunotherapy and juxtapose the clinical use of checkpoint inhibitors against chronically dysfunctional T cells and the acute T cell response to oncolytic viruses.

AB - Systemic viroimmunotherapy activates endogenous innate and adaptive immune responses against both viral and tumor antigens. We have shown that therapy with vesicular stomatitis virus (VSV) engineered to express a tumor-associated antigen activates antigen-specific adoptively transferred T cells (adoptive cell therapy, ACT) in vivo to generate effective therapy. The overall goal of this study was to phenotypically characterize the immune response to VSV+ACT therapy and use the information gained to rationally improve combination therapy. We observed rapid expansion of blood CD8+ effector cells acutely following VSV therapy with markedly high expression of the immune checkpoint molecules PD-1 and TIM-3. Using these data, we tested a treatment schedule incorporating mAb immune checkpoint inhibitors with VSV+ACT treatment. Unlike clinical scenarios, we delivered therapy at early time points following tumor establishment and treatment. Our goal was to potentiate the immune response generated by VSV therapy to achieve durable control of metastatic disease. Despite the high frequency of endogenous PD-1+ TIM-3+ CD8+ T cells following virus administration, antibody blockade did not improve survival. These findings provide highly significant information about response kinetics to viroimmunotherapy and juxtapose the clinical use of checkpoint inhibitors against chronically dysfunctional T cells and the acute T cell response to oncolytic viruses.

KW - checkpoint inhibitors

KW - oncolytic virotherapy

KW - tumor therapy

UR - http://www.scopus.com/inward/record.url?scp=85017023093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017023093&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2017.01.023

DO - 10.1016/j.ymthe.2017.01.023

M3 - Article

VL - 25

SP - 962

EP - 975

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -